Overview

Buserelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist that has been clinically approved for the treatment of hormone-dependent conditions since the 1980s. As a potent LHRH (luteinizing hormone-releasing hormone) analog, buserelin initially stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), followed by receptor desensitization and subsequent suppression of gonadal hormone production.

Clinically, buserelin is primarily used in the treatment of advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The peptide achieves therapeutic effects through chemical castration in men (reducing testosterone to castrate levels) and ovarian suppression in women (reducing estrogen production). This mechanism makes it valuable in managing hormone-sensitive cancers and reproductive disorders.

Due to its potent hormonal effects, buserelin is prohibited by the World Anti-Doping Agency (WADA) and is strictly regulated as a prescription medication in most jurisdictions.

Mechanism of Action

Buserelin functions as a synthetic analog of naturally occurring GnRH, with structural modifications that increase potency and duration of action compared to the endogenous hormone. The peptide contains a D-serine substitution at position 6 and an ethylamide group at the C-terminus, which enhance receptor binding affinity and resistance to peptidase degradation.

Upon administration, buserelin binds to GnRH receptors in the anterior pituitary gland with approximately 50-100 times greater potency than natural GnRH. Initially, this binding stimulates the release of stored LH and FSH, causing a temporary surge in gonadal hormone production (testosterone in men, estrogen in women). This initial stimulation phase typically lasts 7-14 days.

With continued administration, GnRH receptors become desensitized and downregulated, leading to a paradoxical suppression of LH and FSH release. This receptor desensitization results in chemical castration, with testosterone levels in men dropping to less than 1 ng/mL (castrate levels) and estrogen levels in women falling to postmenopausal ranges. The suppressive effects are maintained throughout treatment and are generally reversible upon discontinuation.

Research Summary

Extensive clinical research supports buserelin's efficacy and safety profile across multiple indications. Over 100 human studies have been conducted, with 5 major Phase III trials currently registered for prostate cancer treatment combinations.

Key Studies

Clinical Efficacy Studies: A comprehensive 1990 review in Drugs journal analyzed buserelin's pharmacodynamic and pharmacokinetic properties across multiple clinical trials. The analysis demonstrated consistent achievement of castrate testosterone levels (≤1 ng/mL) in 95% of prostate cancer patients within 3-4 weeks of treatment initiation. Response rates for symptom improvement ranged from 60-80% in advanced prostate cancer patients.

Delivery System Research: Multiple studies have investigated optimized delivery methods for buserelin. A 1996 Pharmaceutical Research study demonstrated successful buccal delivery using glycodeoxycholate as an absorption enhancer in pigs, achieving bioavailability comparable to subcutaneous injection. A 2000 study in the same journal showed that N-trimethylated chitosan chloride significantly improved intestinal permeation in both Caco-2 cell models and rat studies.

Stability and Formulation: A 2014 International Journal of Pharmaceutics study conducted comprehensive degradation kinetics analysis under dry heat conditions, establishing optimal storage parameters and identifying primary degradation pathways. This research supports current stability recommendations for pharmaceutical formulations.

Ongoing Clinical Trials: Current Phase III trials (NCT04513717, NCT05050084) are evaluating buserelin in combination with radiation therapy for high-risk and unfavorable intermediate-risk prostate cancer, building on earlier successful combination protocols.

Dosage Guidelines

Buserelin dosing varies significantly based on indication, administration route, and treatment phase. Clinical protocols typically involve higher initial doses followed by maintenance regimens.

Administration Notes:

• Subcutaneous injection is the most reliable route for consistent bioavailability
• Intranasal administration requires proper technique and has variable absorption (1-3% bioavailability)
• Treatment should not be interrupted once therapeutic suppression is achieved
• Initial tumor flare may occur in first 2 weeks; antiandrogen co-treatment may be required

Safety Profile

Buserelin's safety profile is well-established through decades of clinical use, though significant hormonal side effects are expected due to its mechanism of action.

Common Side Effects (>10% incidence):

• Hot flashes and sweating (80-90% of patients)
• Decreased libido and erectile dysfunction in men
• Mood changes and depression
• Fatigue and weakness
• Injection site reactions

Serious Side Effects (1-10% incidence):

• Bone density reduction with long-term use
• Cardiovascular effects (rare)
• Initial tumor flare in cancer patients
• Severe depression or suicidal ideation

Long-term Considerations: Extended use (>6 months) requires monitoring of bone density, lipid profiles, and cardiovascular health. Calcium and vitamin D supplementation is recommended for all patients on chronic therapy.

Monitoring Requirements:

• Hormone levels (testosterone, estradiol) at 4, 8, and 12 weeks, then every 3 months
• Bone density annually for treatments >6 months
• PSA levels in prostate cancer patients
• Liver function tests every 6 months

Stacking

Buserelin is typically used as monotherapy or in carefully designed clinical protocols rather than experimental stacking regimens. Approved combination therapies focus on medical indications.

Established Medical Combinations:

• Antiandrogens (bicalutamide, flutamide): Used for 2-4 weeks to prevent initial tumor flare in prostate cancer
• Calcium/Vitamin D: Standard supplementation to mitigate bone loss
• Bisphosphonates: For patients at high risk of osteoporosis

Research Combinations: Current clinical trials are evaluating buserelin with radiation therapy and novel androgen receptor antagonists for enhanced prostate cancer treatment outcomes.

Important Note: Buserelin should only be used under medical supervision for approved indications. Unsupervised use for performance enhancement or bodybuilding purposes is dangerous and prohibited by anti-doping regulations.

References

1. [Buserelin]. (1994). Deutsche medizinische Wochenschrift (1946). DOI PubMed
2. Dry heat forced degradation of buserelin peptide: kinetics and degradant profiling. (2014). International journal of pharmaceutics. DOI PubMed
3. Dosage of buserelin. (2000). The Journal of reproductive medicine. PubMed
4. Management of fibroids. (1992). Current opinion in obstetrics & gynecology. PubMed
5. In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. (1996). Pharmaceutical research. DOI PubMed
6. Peroral delivery systems based on superporous hydrogel polymers: release characteristics for the peptide drugs buserelin, octreotide and insulin. (2002). European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. DOI PubMed
7. Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile. (1990). Drugs. DOI PubMed
8. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats). (2000). Pharmaceutical research. DOI PubMed
9. [Goserelin]. (1990). Ugeskrift for laeger. PubMed
10. [Buserelin (Suprefact)]. (1986). Ugeskrift for laeger. PubMed